Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose-Escalation, Dose-Expansion, Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)

NCT03235570 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT03235570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03235570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose-Escalation, Dose-Expansion, Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)
Lead sponsor
Incyte Corporation
Phase
Phase 1
Overall status
Completed
Start date
August 1, 2017
Completion date
March 4, 2020
Enrollment
44 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors